Pharma industry loses on Medicare price negotiations
The pharmaceutical industry suffered a series of separate court losses this week, as companies and trade groups tried to fight Medicare drug price negotiation.
Three separate federal courts ruled against the pharmaceutical industry this week, with some cases having previously been dismissed.
A federal judge dismissed the U.S. Chamber of Commerce’s lawsuit challenging Medicare negotiations a year ago, and this ruling was upheld Wednesday by the Sixth Circuit Court of Appeals.
The suit was dismissed on the basis that some of the plaintiffs — the Dayton Area Chamber of Commerce, the Ohio Chamber of Commerce, and the Michigan Chamber of Commerce — lacked standing to sue.
While the appeals court clarified that local and state organizations can sue over federal laws that impact them, it still found that the case was improperly filed. The court agreed that the U.S. Chamber of Commerce had standing to sue, but it would need to file a new lawsuit in a separate venue.
On Thursday, Medicare negotiation lawsuits challenging theconstitutionality of the program were both ruled against.
PhRMA, another trade group, saw its lawsuit dismissed by a Texas federal judge who found that the organization had failed to demonstrate irreparable harm or constitutional violations stemming from Medicare negotiations.
In Connecticut, the U.S. 2nd Circuit Court of Appeals upheld a decision from last year against the pharmaceutical company Boehringer Ingelheim. Three of the company’s products have been selected for Medicare negotiation.
As has been the case in other rulings, such as the one in Texas, the court relied on the fact that participation in Medicare is entirely voluntary, meaning companies are not being deprived of certain rights because of the negotiation program.
When reached for comment by The Hill, PhRMA spokesperson Sarah Ryan said, “We disagree with the district court’s legal assessment. We continue to believe the IRA’s price-setting provisions are unconstitutional.”
With compounding losses in appellate courts, the pharmaceutical industry may begearing up to take Medicare negotiations before the Supreme Court.
Welcome to The Hill’s Health Care newsletter, we’re Nathaniel Weixel, Joseph Choi and Alejandra O’Connell-Domenech — every week we follow the latest moves on how Washington impacts your health.
A longtime shortage of a type of sterile intravenous saline is now resolved, the Food and Drug Administration announced Friday. According to the FDA, sodium chloride 0.9% injection products have been in shortage since 2018. The shortage was exacerbated when Hurricane Helene flooded a Baxter manufacturing plant in Marion, N.C. last fall what was responsible for 60 percent of the IV fluid in the country. “This marks a …
The Trump administration plans to incinerate more than $9.7 million worth of contraceptives funded by the U.S. Agency for International Development (USAID) that have been lying in a warehouse in Belgium since President Trump’s order freezing foreign aid and shutting down USAID. The U.S. government is spending more than $160,000 to burn the mix of birth control pills, shots, implants, and IUDs at a facility in France that …
MSNBC pundit Joe Scarborough tangled with Rep. Mike Lawler (R-N.Y.) over recent cuts to Medicaid passed by Congress as part of President Trump’s spending bill.
